MedRx Co., Ltd (TYO:4586)
112.00
-1.00 (-0.88%)
Feb 13, 2026, 3:30 PM JST
MedRx Revenue
MedRx had revenue of 100.00M JPY in the quarter ending September 30, 2025, with 316.67% growth. This brings the company's revenue in the last twelve months to 120.00M, down -52.94% year-over-year. In the year 2024, MedRx had annual revenue of 257.00M with 786.21% growth.
Revenue (ttm)
120.00M
Revenue Growth
-52.94%
P/S Ratio
55.41
Revenue / Employee
5.45M
Employees
22
Market Cap
6.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.00M | 228.00M | 786.21% |
| Dec 31, 2023 | 29.00M | -30.00M | -50.85% |
| Dec 31, 2022 | 59.00M | 51.00M | 637.50% |
| Dec 31, 2021 | 8.00M | -107.00M | -93.04% |
| Dec 31, 2020 | 115.00M | -54.00M | -31.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.05B |
| Nippon Chemiphar | 32.52B |
| Morishita Jintan | 12.90B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 5.94B |
| WDB coco | 4.98B |
| SymBio Pharmaceuticals | 1.31B |